{
    "symbol": "TYME",
    "quarter": 3,
    "year": 2022,
    "date": "2022-02-11 10:22:04",
    "content": " The OASIS trial was an open label Phase II trial examining SM-88 with methoxsalen, phenytoin, and sirolimus or MPS in patients with metastatic hormonal positive, HR positive HER2 negative advanced breast cancer who have received two prior hormonal therapies and failed or progressed after receiving a CDK4/6 inhibitor agent. The year-over-year decrease the loss is of $5 million for the nine-month period is due to the variable net values of $2.4 million related to the non-cash warrant related expenses and lower operating costs of $2.6 million, reflecting lower research and development expenses of $1.9 million due to lower ongoing trial costs and lower general administrative expenses of $0.7 million."
}